Kubota Pharmaceutical Holdings Co. Ltd. · TSE:4596
Kubota Pharmaceutical — Acucela — Merger or Acquisition (March 2016)
9 slides from Kubota Pharmaceutical's merger presentation, Mar 29, 2016
Slide 1: FYE2015 Analyst Meeting
FYE2015 Analyst Meeting Acucela Inc. Tokyo, Japan March 29, 2016 Acucela is a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases affecting millions of people worldwide.
Slide 2: Disclaimer and Additional Information
DISCLAIMER AND ADDITIONAL INFORMATION Certain statements contained in this presentation and made in connection therewith are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Li
Slide 3: Disclaimer and Additional Information
DISCLAIMER AND ADDITIONAL INFORMATION the Company’s clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in the Company’s clinical trial plans or limit the potential benefits of its investigational product candidates; th
Slide 4: Disclaimer and Additional Information
DISCLAIMER AND ADDITIONAL INFORMATION Acucela Inc. and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in connection with the Inversion. Information about these persons is set forth in the Company’s Annual Report on
Slide 5: Recent Highlights
Recent Highlights Date Highlights May 13 ‘15 Acucela Announces Publication of Pre-clinical Data for Emixustat Hydrochloride (PLOS ONE) Acucela Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride (June Jun 3 ‘15 edition of RETINA) Jul 2 ‘15 Acucela Hires Roger Girard
Slide 6: Corporate Strategy
Corporate Strategy Continuous development of the current pipeline and increase in business development activities to expand the portfolio Emixustat for GA secondary to dry AMD Current − June 2016 disclosure on top-line data results of Phase 2b/3 trial − Obtained feedback from European regulatory age
Slide 7: Inversion
Dnt ACUCELA init for sight Inversion
Slide 8: Potential Benefits of the Inversion
Potential Benefits of the Inversion • Potential benefits that would increase shareholder: − Increased availability, quantity and prominence of information about the Holding Company for Japanese investors, which can be made available in the Kaisha Shikiho and Nikkei Kaisha Joho, two publications freq
Slide 9: Anticipated Schedule and Proposed Scheme
Anticipated Schedule and Proposed Scheme 1: Current Status 2: Triangular Merger Japan Company’s U.S. Japan Company’s U.S. Shareholders Shareholders Distribution of Acucela Inc. Acucela Inc. Shares of the Holding Company Triangular Holding Company Holding Company Merger • The Company is the dissolvin